simvastatin trial summary

Acute coronary syndrome

Early initiation: 1 trials - A to Z

No demonstrated result

Aortic stenosis

All type of patients: 1 trials - SEAS

No demonstrated result

CABG surgery

Preoperative statins: 1 trials - Christenson

No demonstrated result

Cardiovascular prevention

All chronical situations: 10 trials - Mondillo - Aronow - MAAS - HPS - 4S - Node - Hong - Landmesser - CIS - SEARCH

No demonstrated result

All cause death by 15% (fully demonstrated)

suggested cardiovascular events by 26% (not demonstrated)

suggested Cardiovascular death by 20% (not demonstrated)

suggested stroke (fatal and non fatal) by 25% (not demonstrated)

suggested Coronary event by 27% (not demonstrated)

suggested Coronary death and non fatal MI by 26% (not demonstrated)

suggested Coronary death by 22% (not demonstrated)

suggested cardiac death by 41% (not demonstrated)

suggested Non fatal MI by 36% (not demonstrated)

No demonstrated result

Rhabdomyolysis by 1667% (harmful effect)

suggested Non fatal MI by 14% (not demonstrated)

See more clinical conditions

Diabetic patients : 3 trials - HPS (diabetic sub group) - 4S (diabetic sub group) - HPS (diabetic primary prevention sub group)

No demonstrated result

suggested cardiovascular events by 19% (not demonstrated)

suggested stroke (fatal and non fatal) by 23% (not demonstrated)

suggested Coronary event by 28% (not demonstrated)

Elderly: 2 trials - 4S (elderly subgroup) - HPS (elderly subgroup)

No demonstrated result

suggested stroke (fatal and non fatal) by 29% (not demonstrated)

suggested Coronary death by 19% (not demonstrated)

suggested Non fatal MI by 29% (not demonstrated)

suggested Revascularization by 38% (not demonstrated)

suggested All cause death by 14% (not demonstrated)

High risk patients with or without LDL cholesterol elevation: 1 trials - HPS

All cause death by 12% (fully demonstrated)

suggested Cardiovascular death by 17% (not demonstrated)

suggested stroke (fatal and non fatal) by 24% (not demonstrated)

suggested Coronary event by 26% (not demonstrated)

suggested Coronary death and non fatal MI by 26% (not demonstrated)

suggested Coronary death by 17% (not demonstrated)

suggested Non fatal MI by 38% (not demonstrated)

Patient with related disease: 1 trials - SEAS

No demonstrated result

Patients with prior MI or with CHD: 5 trials - HPS - 4S - A to Z - CIS - SEARCH

All cause death by 14% (fully demonstrated)

suggested cardiovascular events by 23% (not demonstrated)

suggested Cardiovascular death by 20% (not demonstrated)

suggested stroke (fatal and non fatal) by 25% (not demonstrated)

suggested Coronary event by 27% (not demonstrated)

suggested Coronary death and non fatal MI by 26% (not demonstrated)

suggested Coronary death by 22% (not demonstrated)

suggested cardiac death by 35% (not demonstrated)

suggested Non fatal MI by 32% (not demonstrated)

No demonstrated result

Rhabdomyolysis by 1667% (harmful effect)

suggested Non fatal MI by 14% (not demonstrated)

Post stroke (or TIA) : 1 trials - HPS (post troke sub group)

No demonstrated result

suggested cardiovascular events by 21% (not demonstrated)

Primary prevention: 1 trials - HPS (diabetic primary prevention sub group)

No demonstrated result

Secondary prevention: 5 trials - MAAS - HPS - 4S - CIS - SEARCH

All cause death by 15% (fully demonstrated)

suggested cardiovascular events by 26% (not demonstrated)

suggested Cardiovascular death by 20% (not demonstrated)

suggested stroke (fatal and non fatal) by 25% (not demonstrated)

suggested Coronary event by 27% (not demonstrated)

suggested Coronary death and non fatal MI by 26% (not demonstrated)

suggested Coronary death by 22% (not demonstrated)

suggested cardiac death by 41% (not demonstrated)

suggested Non fatal MI by 36% (not demonstrated)

No demonstrated result

Rhabdomyolysis by 1667% (harmful effect)

suggested Non fatal MI by 14% (not demonstrated)

Women: 1 trials - HPS (women subgroup)

No demonstrated result

suggested Coronary event by 24% (not demonstrated)

Diabetes type 2

Diabetic patients with or withour hypercholesterolemia: 2 trials - HPS (diabetic sub group) - 4S (diabetic sub group)

No demonstrated result

suggested cardiovascular events by 19% (not demonstrated)

suggested stroke (fatal and non fatal) by 23% (not demonstrated)

suggested Coronary event by 28% (not demonstrated)

See more clinical conditions

Heart failure

All type of patients: 3 trials - Node - Hong - Landmesser

No demonstrated result

Peripheral vascular diseases

All type of patients: 3 trials - HPS (sub group) - Mondillo - Aronow

No demonstrated result

suggested Cardiovascular death by 17% (not demonstrated)

suggested Revascularization by 15% (not demonstrated)

suggested All cause death by 12% (not demonstrated)

Post myocardial infarction

All type of patients: 1 trials - 4S

All cause death by 29% (fully demonstrated)

suggested cardiovascular events by 26% (not demonstrated)

suggested Cardiovascular death by 34% (not demonstrated)

suggested stroke (fatal and non fatal) by 29% (not demonstrated)

suggested Coronary event by 31% (not demonstrated)

suggested Coronary death by 41% (not demonstrated)

suggested cardiac death by 41% (not demonstrated)

suggested Non fatal MI by 33% (not demonstrated)

Post stroke

All type of patients: 1 trials - HPS (post troke sub group)

No demonstrated result

suggested cardiovascular events by 21% (not demonstrated)

Simvastatin cholesterol lowering intervention

Zocor

Acute coronary syndrome

Aortic stenosis

CABG surgery

Cardiovascular prevention

Diabetes type 2

Heart failure

Peripheral vascular diseases

Post myocardial infarction

Post stroke